Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

Ray, Michael E

Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. [electronic resource] - Journal of the National Cancer Institute Feb 2009 - 228-36 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural

1460-2105

10.1093/jnci/djn489 doi


Aged
Androgen Antagonists--administration & dosage
Antineoplastic Agents, Hormonal--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor--blood
Chemotherapy, Adjuvant
Disease-Free Survival
Dose Fractionation, Radiation
Endpoint Determination--methods
Flutamide--administration & dosage
Follow-Up Studies
Goserelin--administration & dosage
Humans
Karnofsky Performance Status
Male
Middle Aged
Neoadjuvant Therapy--methods
Neoplasms, Hormone-Dependent--blood
Prostate-Specific Antigen--blood
Prostatic Neoplasms--blood
Radiotherapy, Adjuvant
Research Design
Treatment Failure
Treatment Outcome